FI95259C - Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi - Google Patents

Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi

Info

Publication number
FI95259C
FI95259C FI914015A FI914015A FI95259C FI 95259 C FI95259 C FI 95259C FI 914015 A FI914015 A FI 914015A FI 914015 A FI914015 A FI 914015A FI 95259 C FI95259 C FI 95259C
Authority
FI
Finland
Prior art keywords
pyrrolo
pyrimidin
dihydro
ones
amino
Prior art date
Application number
FI914015A
Other languages
English (en)
Swedish (sv)
Other versions
FI95259B (fi
FI914015A0 (fi
Inventor
Iii John A Secrist
Mark David Erion
John A Montgomery
Steven E Ealick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of FI914015A0 publication Critical patent/FI914015A0/fi
Application granted granted Critical
Publication of FI95259B publication Critical patent/FI95259B/fi
Publication of FI95259C publication Critical patent/FI95259C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI914015A 1989-02-27 1991-08-26 Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi FI95259C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31606389A 1989-02-27 1989-02-27
US31606389 1989-02-27
US9001021 1990-02-27
PCT/US1990/001021 WO1990010631A1 (en) 1989-02-27 1990-02-27 9-substituted-8-unsubstituted-9-deazaguanines

Publications (3)

Publication Number Publication Date
FI914015A0 FI914015A0 (fi) 1991-08-26
FI95259B FI95259B (fi) 1995-09-29
FI95259C true FI95259C (fi) 1996-01-10

Family

ID=23227309

Family Applications (1)

Application Number Title Priority Date Filing Date
FI914015A FI95259C (fi) 1989-02-27 1991-08-26 Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi

Country Status (15)

Country Link
US (2) US5565463A (fi)
EP (1) EP0460116B1 (fi)
JP (1) JP2760364B2 (fi)
KR (1) KR100208315B1 (fi)
AT (1) ATE157363T1 (fi)
AU (1) AU640649B2 (fi)
CA (1) CA2047216C (fi)
DE (1) DE69031337T2 (fi)
DK (1) DK0460116T3 (fi)
ES (1) ES2106732T3 (fi)
FI (1) FI95259C (fi)
HU (1) HU217870B (fi)
NO (1) NO180049C (fi)
RU (1) RU2093513C1 (fi)
WO (1) WO1990010631A1 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072123C (en) * 1989-10-31 2001-06-12 John A. Secrist, Iii Inhibitors of purine nucleoside phosphorylase
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
AU6855594A (en) 1993-06-30 1995-01-24 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5650511A (en) * 1995-12-12 1997-07-22 Biocryst Pharmaceuticals, Inc. Process for the preparation of 9-deazaguanine derivatives
JP2002500658A (ja) * 1997-05-29 2002-01-08 ノバルティス アクチエンゲゼルシャフト ２−アミノ−７−（１−置換−２−ヒドロキシエチル）−３，５−ジヒドロピロロ［３，２−ｄ］ピリミジン−４−オン
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
UA104579C2 (uk) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
US9452217B2 (en) 2013-06-22 2016-09-27 Nitor Therapeutics Methods for potentiating immune response for the treatment of infectious diseases and cancer
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
IE60433B1 (en) * 1986-08-26 1994-07-13 Warner Lambert Co Novel 9-deazaguanines
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Also Published As

Publication number Publication date
EP0460116A4 (en) 1992-05-13
CA2047216A1 (en) 1990-08-28
US5565463A (en) 1996-10-15
DK0460116T3 (da) 1998-03-30
JP2760364B2 (ja) 1998-05-28
NO913332D0 (no) 1991-08-26
ES2106732T3 (es) 1997-11-16
AU640649B2 (en) 1993-09-02
DE69031337T2 (de) 1998-03-05
EP0460116A1 (en) 1991-12-11
NO913332L (no) 1991-08-26
RU2093513C1 (ru) 1997-10-20
FI95259B (fi) 1995-09-29
NO180049C (no) 1997-02-05
US5721240A (en) 1998-02-24
NO180049B (no) 1996-10-28
KR920701209A (ko) 1992-08-11
AU5524890A (en) 1990-10-09
FI914015A0 (fi) 1991-08-26
KR100208315B1 (ko) 1999-07-15
CA2047216C (en) 1999-03-30
JPH04503675A (ja) 1992-07-02
ATE157363T1 (de) 1997-09-15
HU217870B (hu) 2000-04-28
EP0460116B1 (en) 1997-08-27
WO1990010631A1 (en) 1990-09-20
HUT58737A (en) 1992-03-30
DE69031337D1 (de) 1997-10-02

Similar Documents

Publication Publication Date Title
FI95259C (fi) Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi
CA2009637A1 (en) Substituted-1,3-oxathiolanes with antiviral properties
HU9501825D0 (en) Process for preparing substituted 1,3-oxathiolanes with antiviral properties
DE3270118D1 (en) 6-alpha-methyl-prednisolone derivatives, their preparation and utilization
NO20084343L (no) Fremgangsmate for fremstilling av 6-(4-fenylbutoksy)heksylaminderivater
ZM987A1 (en) New dihydrobenzofuran and chroman-carboxamide derivatives,processes for the preparation thereof and use thereof as neuroleptics
ES8701773A1 (es) Procedimiento de preparar derivados de nucleosidos y purinas8-substituidos
YU21391A (sh) Triciklični-ciklični amini kao novi inhibitori holinesteraze
ES8800920A1 (es) Un procedimiento para preparar un derivado de 1,5-benzotiazepina
MY116824A (en) Antivaral,highly water soluble,stable,crystalline salts of 2'',3''-dideoxyinosine monohydrate,2'',3''-dideoxy-2'' ,3''-didehydrothymidine monohydrate and 2'',3''-dideoxy-2''-fluoroinosine hemihydrate
NO176177C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-amino-tetrahydroisokinolinderivater
SE8602880L (sv) Farmakologiskt verksam forening

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: BIOCRYST PHARMACEUTICALS, INC.

BB Publication of examined application